Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma

[1]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[2]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[3]  P. Sharma,et al.  Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma , 2020, Nature Medicine.

[4]  Amber C. Donahue,et al.  Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial , 2020, Nature Medicine.

[5]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[6]  J. Wargo,et al.  B cells are associated with survival and immunotherapy response in sarcoma , 2020, Nature.

[7]  D. Schadendorf,et al.  Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.

[8]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[9]  J. Reeves,et al.  Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma , 2018, Nature Medicine.

[10]  Paul T. Spellman,et al.  The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma , 2018, Cell reports.

[11]  E. Plimack,et al.  Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Yusuke Nakamura,et al.  Characterization of the cryoablation-induced immune response in kidney cancer patients , 2017, Oncoimmunology.

[13]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[14]  Janice S. Sung,et al.  A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling , 2016, Clinical Cancer Research.

[15]  H. Tesch,et al.  Systemic therapy in metastatic renal cell carcinoma , 2016, World Journal of Urology.

[16]  P. Ross-Macdonald,et al.  Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.

[17]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[18]  D. Schadendorf,et al.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[20]  J. Wolchok,et al.  Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy , 2013, Cancer Immunology Research.

[21]  P. Novotny,et al.  Percutaneous image‐guided cryoablation of painful metastases involving bone , 2013, Cancer.

[22]  A. Hauschild,et al.  Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Allison,et al.  CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection , 2012, Oncoimmunology.

[24]  A. Goodman,et al.  Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. , 2012, Journal of vascular and interventional radiology : JVIR.

[25]  A. Thakur,et al.  Induction of Specific Cellular and Humoral Responses Against Renal Cell Carcinoma After Combination Therapy With Cryoablation and Granulocyte-Macrophage Colony Stimulating Factor: A Pilot Study , 2011, Journal of immunotherapy.

[26]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[27]  J. Wolchok,et al.  Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial , 2010, Clinical Cancer Research.

[28]  John F. Ward,et al.  Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues , 2009, Proceedings of the National Academy of Sciences.

[29]  M. Sabel,et al.  Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. , 2009, Cryobiology.

[30]  P. Sharma,et al.  CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients , 2008, Proceedings of the National Academy of Sciences.

[31]  S. Rosenberg,et al.  Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis , 2007, Journal of immunotherapy.

[32]  P. Srivastava,et al.  Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. , 2000, International immunology.

[33]  C. Baird.  The pilot study. , 2000, Orthopedic nursing.

[34]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[35]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[36]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[37]  J. Lunceford,et al.  IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .

[38]  P. Sharma,et al.  Immunological response to renal cryoablation in an in vivo orthotopic renal cell carcinoma murine model. , 2010, The Journal of urology.

[39]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.